Release Fact posted the article “Eric Lefkofsky’s Tempus Labs Uses Big Data Analytics to Revolutionize Cancer Medicine”. In the article, Blair Harris describes the top biotech start-up and its recent improvements in technology.
The company began in 2015 and has quickly risen to the top of the industry with its combination of gene editing technology and machine learning. Tempus labs became known as a leading provider of gene sequencing to provide specialized cancer treatment regimens. It works in collaboration with the National Cancer Institute to organize a library of data paired with genomic sequencing to provide more actionable insights for individualized treatment plans.
However, it has also had several biotechnologies approved by the FDA recently. One pairs gene editing and gene therapy to treat a form of inherited blindness like Hunter syndrome. By focusing on specific gene mutations, the company can create a vivo manipulation.
Tempus is also quickly advancing technology in identifying skin cancers. Their machine learning algorithms have become almost as capable as physicians, equaling their abilities to find and diagnose both malignant and benign melanoma.
They also approved FDA approval for a watch that monitors blood pressure. It simply reads blood pressure by interpreting information from the radial artery. Tempus also has AI technology for diagnosing eye issues in a cheaper way than clinicians. The algorithms identify diabetic retinopathy and other eye complications.
Tempus was co-founded in 2015 by Eric Lefkofsky. The company quickly became evaluated at $700 million because of its innovations of a comprehensive analytical machine learning platform with which doctors and physicians can interact. The purpose of the company is to use information from those who have experienced cancer before and apply it to current patients. It helps physicians create real-time precision medicine treatment plans for each individual while using metadata to discover the best methodology.
Eric Lefkofsky created the company after having a close experience with the pain of cancer treatment when a close acquaintance went through the process. Lefkofsky is known for his work as a serial entrepreneur, starting many companies in transportation, advertising technology, venture capital, and analytics. Lefkofksy is also a devoted philanthropist.
To know more click: here.
Chairman of Urology, Chief of Robotic Surgery, fellowship in proctology at Memorial Sloan Kettering Center is only a sample of Dr. David Samadi resume. Currently employed at Lenox Hill Hospital in New York, NY, Dr. Samadi has performed thousands minimally invasive procedures and invented his own techniques to prostate removal through robotic surgical advancements. He truly is a surgeon in a class of his own.
Being a world class urologist, Dr. Samadi was able to personally create the SMART method for prostate removal. The Samadi Modified Advance Robotic Technique is a specially designed procedure created to drastically decrease the post surgical side effects men disdain. It is very common for men, without using the SMART method, to lose sexual function in their genitalia. Incontinence and impotence create a barrier for men desiring the surgery. SMART allows for the prostate to be removed with minimal damage done to the surrounding nerves. The robotic advancement allows for more precise work and more men are seeking this method.
He is skilled in identifying cancer in the prostate, kidney, and bladder. He is more than capable in his ability to perform laparoscopic radical prostatectomy or the same procedure of the robotic nature. He believes in the advancement of technology in better the health outcomes of his patients. He also believes in the influence of social media and televisions ability out pour data into nearly countless individuals.
With the intent of spreading the knowledge and health awareness he and other colleagues had to make the world aware of unknown medical knowledge. Meanwhile providing communities with information they otherwise would never receive. Dr. Samadi has always had an entrepreneurial mindset. Settling for just the day to day in the trenches grunt work is honorable, but not enough. His practice has been taken worldwide with the implementation of Dr. Samadi TV. He pools the medical knowledge of several guest physicians to share their views and clinical expertise on different subject matters to empower through education our world. Some people avoid doctors offices in fear of the news they may receive. However, Dr. Samadi TV brings the information packaged in a way anyone can digest, and desire more information or possible intervention in their lives.
He truly is a trusted surgeon, Mitt Romney whom had been diagnosed with prostate cancer had a clean prognosis recently. Dr. Samadi helped with his surgery and state he is doing well. Our world leaders trust Dr. Samadi, magazines call him Best Doctor, and patients have awarded him the Patient’s Choice Award. Truly Dr. Samadi desires the best for humanity.
Dr. David Samadi’s Facebook Page: www.facebook.com/DrDavidSamadi/
Eric Lefkofsky is much more than a teacher and philanthropist. He is the co-founder and CEO of a company named Tempus. Tempus is a company that takes patient data and uses it to help try to find patterns in diseases like cancer and the like. Tempus uses its own system in order to look at the data and help figure out the genomic sequences used in how cancer spreads through the body. By using such data doctors can create therapies for each individual patient depending on the type of cancer that they have. In an article for the Alive newspaper, Eric Lefkofsky why using data is so important when it comes to battling cancer.
How does the CEO of Tempus go about figuring out the complexities of cancer? Eric Lefkofsky’s answer is a simple and direct one. the answer for him is information. Bey combining forces Eric Lefofksy’s Tempus and other healthcare companies can use the information at hand to figure out what makes cancer tick and how to create a personal treatment for each individual. By using the information from patients and the latest analysis of molecular data, doctors can learn about treatments that have worked for patients and help break through the cancer barrier. Lefkofsky hopes that by sharing data with other companies a more effective approach can be taken when it comes to cancer treatment and care.
Eric Lefkofsky doesn’t want to stop at just cancer. He wants to give the doctors of the future a leg up when it comes to treatment and personalized medicine. He hopes in the coming years that the data and analysis methods used in cancer research can be used for other diseases as well. With the help of current gene therapies as well as patient information can help with neurological problems and not just cancer care.
Eric Lefkofsky is well on his way with his team at Tepus to tackling the problem of cancer in today’s society. He believes that information is the key to unlocking the mystery of cancer. He will keep pressing forward until the right answer is found.
Read More: www.crunchbase.com/person/eric-lefkofsky
Cancer Treatment Centers of America put a lot of effort into their broad cancer education programs. This dedicated cancer research and top cancer care provider is involved in an exciting new joint educational venture with long respected WebMD. This site allows greater access to informed choices in the wide variety of cancer treatment programs. Cancer Treatment Centers of America has always sought to lead by example. This exciting venture is making headlines in many cancer care networks across the United States. CTCA also provides valuable educational materials to those living in other countries across the seas.
This joint effort to advance educational information is setup to be accessed from workplaces, schools, public facilities and from home environments. Cancer patients are often flabbergasted by the sheer volume of highly technical information that they receive from their healthcare providers. Websites like this one at WebMD gets credible healthcare educational materials, resource information and treatment details to those patients desiring a way to decipher the complex medical language. They can now simply look up wanted information on their lab results, medication changes, new treatments, support directly related to cancer survival and more. Cancer Treatment Centers of America is investing a lot of funds and time into this goal of bringing better cancer care education in an environment where patients feel secure.
Those cancer patients with Internet access are overjoyed when they discover how easy and beneficial gaining information in this user-friendly manner is. Cancer Treatment Centers of America uses many methods for spreading their finds on cancer care to communities that need more information. WebMD is a phenomenal wealth of interesting information that is relevant to patients, friends, professional healthcare employees and the ordinary individual just wanting to learn about cancer. CTCA is hoping to provide even more articles on cancer via WebMD.
Tempus CEO and philanthropist have been in the line of improving data management of Cancer through technology, a venture that was more than necessary. The billionaire was recently captioned saying that he is willing to invest over $100 million in Tempus to realize its mission. Tempus Company is focused on saving the lives of cancer patients through customized cancer treatments using genomic sequencing.
Tempus has raised a total funding of $130 million since it began in the year 2015. The current estimate valuation of Tempus is said to be at approximately $700 million though Eric Lefkofsky has not confirmed this information. Co-founder Brad Keywell and Lefkofsky remain the largest individual investors in Tempus. The company continues to add on investors and also receives funding New Enterprise Associates and Revolution Growth. The loss of a loved one motivated Lefkofsky venture into health. Tempus has so far made partnerships with the Mayo Clinic, The Cleveland Clinic, and the Duke University School of Medicine among others.
Eric Lefkosky has founded and co-founded some successful companies. Among his currently trading corporations are Echo Global Logistics, MediaBank, Groupon.com and the new Tempus. Among the groups that have made tremendous success include Groupon.com which was announced as the fastest growing company by Forbes. Eric still maintains his position as the Chairman of Groupon.com after stepping down as CEO.
Lefkofsky is on the board of directors of various institutions which include The Art institution of Chicago, The Museum of Science and Industry, Children Memorial Hospital and World Business Chicago. He is also a trustee of Steppenwolf Theater Company. He was also involved in the committee that was responsible for the 206 summer Olympics in Chicago. Lefkofsky has also been involved in philanthropic work. In 2006, He, together with His wife Elizabeth founded The Lefkofsky foundation which primary focus is on children. The foundation has funded over 50 organizations so far and continued to so. The Lefkofskys also joined the Giving Pledge in 2013. Lefkofsky hopes to help in saving for more cancer patients through Tempus. He is positive about the company moving its agenda on a global scale.
IntegraGen is a company that specializes in the conversion of sensitive data from the raw biological forms into genomic data in addition to diagnostic tools made for oncology. The company just announced that the search results of an analysis report concerning miR-31-3p expression are in Oncotarget. The publishing is a step forward towards finding treatment for tumor expressed diseases. The title of the article reads Association between miR-31-3p. The publication is a confirmation of good analysis on miR-31-3p expression levels. The patients with RAS type of wild metastatic cancer can be utilized to conduct diagnostic tool with the aim of identifying patients that will benefit from the tests.
Profile of Research
The peer-reviewed article that was published is a huge contribution towards the evidence –based research on the benefits of miR-31-3p tumors that originate from patients who have metastatic colorectal cancer. According to Mr. Yann Gaston-Mathe, the director in charge of Molecular Diagnostic, the publication of the research findings is a step towards accomplishing the benefits of precision in medicine.
Oncotarget Features Cancer Treatment
Colorectal cancer is the world’s third common cancer found in men. In women, it ranks second. Research has been conducted to find viable treatment for this cancer. The therapies have been put in place to deliver the right information to doctors. Oncotarget just featured an article on the latest treatment therapy. That is why Oncotarget is highly regarded. The scientific journal seeks to share vital data concerning treatment and the new research in different sectors of medicine. As a scientific journal that shares information, Oncotarget is published twice in a week. In other scenarios, it can be printed when a demand is made.
Oncotarget has always featured articles based on the seriousness of the content. The panel in charge of editing and publishing is well versed with the requirements that must be met. Oncotarget is manned by Mikhail Blagosklonny, a research scientist. His great leadership has been helpful in growing the data base of the journal. Most medical practitioners are turning to the journal to seek vital data. Through Oncotarget, medical practitioners have found a medium through which they can share vital data on treatment.
Mikhail Blagosklonny runs Oncotarget which is one of the largest and most-progressive medical journals in the world. This journal has been dedicated to ensuring the health and happiness of cancer patients for some time, and there are many people who benefit from the formatting and research content. This article explains why Oncotarget is such a wonderful addition to the libraries of many from the simplest of patient searches to doctor’s offices around the world.
#1: What Does Oncotarget Do?
Oncotarget was created to ensure that all patients would have access to new research in the field of cancer and coancer treatment. It is an online journal that anyone may access at any time, and it has quite a lot of information that is not found in other journals. Someone who wishes to look into this journal will find information on diagnosis, treatment and therapy for cancer patients, and they may use that information to help change their treatment plan or someone else’s.
#2: Who Submits Research?
The Oncotarget brand takes research every day from new writers, and they will publish anything that has passed thei review board. The review board that was created for the Oncotarget brand is rune xclusivelty by Mikhail Blagosklonny. There are many amazing professionals on this board, and they will look over every piece of research to ensure that they understand how it was created, if it has been done properly and what may be changed. They want each study to read well when it comes to them, and they are willing to offer feedback that makes it much easier for authors to change their approach.
#3: Who Benefits?
Anyone who has cancer or has been hit by cancer may read this unique journal. It is a place where the research has been compiled to ensure that cancer may be beaten, and someone who has questions about particular cancers may search the archives to find what they need. There are many people who are unsure of what to do about the diagnosis they have, and they may read some encouraging news about this diagnosis in the journal. This is a safe place for people to come when they have questions, and they may read through every edition of the journal if they have to.
#4: Remaining Cutting Edge
Oncotarget offers space for people to publish their research when they may not have the chance in other publications. The major medical journals are filled with many studies that are taking up space that could be used by others, and Oncotarget offers a bit of this space to all their readers. A chance is given to everyone who is new when they contact Oncotarget and Mikhail Blagosklonny.The Oncotarget journal is one that all cancer patients and family members should read. They have quite a lot of hope in the pages of each edition, and they will find that these studies have been reviewed and vetted as much as possible by the advisory board and their leader in Mikhail Blagosklonny.